Variation in mortality of HIV/SARS-CoV-2 co-infected patients in the Bronx, New York City.
Coronavirus disease 2019 (COVID-19) pandemic has caused tremendous strain on global health care systems and impacted the human quality of life worldwide. HIV patients are vulnerable to certain fatal infection due to their deficient immune functions. Nonetheless, the immunocompromised state may prevent HIV patients from severe hyper-immunity respond to COVID-19. To date, the impact of HIV on the clinical courses and outcomes of COVID-19 is inconclusive, and study answering this matter is evolving. We recently published the case series of nine HIV/SARS-CoV-2 co-infected patients admitted to our hospital during the early-wave of the pandemic in New York City, which contained the worrying mortality at 78%. Herein, we presented the clinical features and outcomes of another five confirmed COVID-19 patients with HIV infection who admitted to our hospital during the resolving pandemic phase of NYC, which showed an improved mortality rate at 20%. Notwithstanding, 60% of patients still had severe COVID-19 complicated with acute respiratory distress syndrome (ARDS) and shock. The extremely high mortality rate in our case series may be due to the mortality biases, the delay in corticosteroids administration, different vulnerability of patients, and the limitation of healthcare resources. This article is protected by copyright. All rights reserved.